Dolutegravir-Based ART — Effective for HIV-2 Infection

In a small single-arm, open-label trial in Portugal, dolutegravir + two NRTIs proved effective and safe for managing HIV-2 infection.

Data are sparse regarding treatment of HIV-2 infection with contemporary ART regimens; moreover, HIV-2 exhibits intrinsic resistance to NNRTIs. Further complicating the management of HIV-2 infection is the fact that plasma HIV-2 RNA levels, when available, typically run very low (often undetectable) compared with HIV-1 levels, often resulting in reliance on CD4 count and clinical assessment to gauge response to ART. Previously, two small studies demonstrated that a first-generation INSTI-based regimen (raltegravir or elvitegravir) was generally effective — but in each study, a case of virologic failure with INSTI resistance occurred. Now, Pacheco et al. (supported by a grant from ViiV Healthcare) have evaluated week-48 responses to a dolute…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Dolutegravir-Based ART — Effective for HIV-2 Infection

Topics

Reviewing Author